A security researcher frustrated with Microsoft has released the BlueHammer Windows zero-day exploit, telling the company, “I ...

Claude Mythos finds thousands of zero-days as Anthropic launches Project Glasswing, enhancing defenses but exposing AI ...

Add Yahoo as a preferred source to see more of our stories on Google. Photo Credit: iStock A Google data center in Minnesota will feature a massive battery that could alter how tech companies get ...

HOUSTON – Tuesday is the last day for Texas families to apply for the state’s new school voucher program, with the application window closing on March 17. The program, known as the Texas Education ...

The tech industry’s expansion of data centers is emerging as a wedge issue in the midterms, as candidates weigh economic opportunity against the associated strain on voters’ utility bills. In the ...

Dominik Bošnjak is a freelance writer from Croatia. He has been writing about games for as long as he can remember and began doing so professionally in 2010 because an opportunity presented itself ...

TALLAHASSEE, Fla. (WCTV/Gray Florida Capital Bureau) - Emergency funding to restore the state’s AIDS Drug Assistance Program is now ready for Gov. Ron DeSantis. The Florida Legislature has passed ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The moratorium could last 18 ...

As companies race to adopt agentic AI to spur innovation and gain efficiency, building the right enterprise data infrastructure has become a critical component of success. In partnership withSAP In ...

Every time Hugh publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from Business ...

U.S. cancer drug developer Day One Biopharmaceuticals (DAWN) has agreed to be acquired by French pharmaceutical group Servier in an all-cash deal worth nearly $2.5B, according to a statement from the ...

As nonprofit-governed Servier continues to make gains with its IDH-mutant glioma med Voranigo, the drugmaker is wading deeper into the rare oncology arena with a new M&A play. Servier on Friday ...